ADAG Adagene ADS (N Shares)

天演宣布出席杰富瑞（Jefferies）中国生物科技线上峰会

天演宣布出席杰富瑞（Jefferies）中国生物科技线上峰会

中国苏州和美国旧金山, Oct. 21, 2021 (GLOBE NEWSWIRE) -- 天演药业（以下简称“公司”或“天演”）（纳斯达克股票代码：ADAG）是一家平台驱动的临床阶段生物制药公司，致力于发现并开发以原创抗体为基石的新型癌症免疫疗法。公司今日宣布，天演联合创始人、首席执行官兼董事长罗培志博士将参加2021年10月 21日线上举行的杰富瑞（Jefferies）中国生物科技峰会，公布公司最新进展并参与一对一的投资者会议。

会议具体信息如下：

发言日期：美国东部时间，2021年10月26日，周二

发言时间：美国东部时间，下午三点

网络直播：（可支持三十天回放）

关于天演药业

天演药业（纳斯达克股票代码：ADAG）是平台驱动并拥有自主平台产出的临床产品开发阶段的生物制药公司，公司致力于发现并开发以原创抗体为基石的新型癌症免疫疗法。借力于计算生物学与人工智能，凭借其全球首创的三体平台技术（新表位抗体NEObody™，安全抗体SAFEbody™及强力抗体POWERbody™），天演药业已建立起聚焦于新型肿瘤免疫疗法的独特原创的抗体产品线，以解决尚未满足的临床需求。天演已和多个全球知名合作伙伴达成了战略合作关系，并以其多种原创前沿科技为合作伙伴的新药研发赋能。

如需了解更多信息，请访问：。

公司联系人：

吴瑛

天演药业

0512-8777-3632 转 8660

投资者联系人：

Bruce Mackle

LifeSci Advisors

(01)646-889-1200



EN
21/10/2021

Underlying

ADAGAdagene ADS (N Shares)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Adagene ADS (N Shares)

 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene Provides Business Update and 2026 Objectives

Adagene Provides Business Update and 2026 Objectives Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026 Unaudited cash and cash equivalents of $74.5 million as of December 31, 2025 anticipated to provide sufficient runway into late 2027 SAN DIEGO and SUZHOU, China, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced year-end unaudited cash and cash equivalents of $74.5 million and prov...

January 23, 2026 1 EN
 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)

Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126) Designation underscores the potential of SAFEbody®-enabled anti-CTLA-4 therapy to address unmet need in MSS colorectal cancer SAN DIEGO and SUZHOU, China, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated muzastotug, in combination with Merck’s (known as MSD outside of the United States and Canada) anti-PD-1 therapy, KEYTRUDA® (pe...

December 16, 2025 1 EN
 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene Announces Licensing Agreement with Third Arc Bio for Developme...

Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology SAN DIEGO and SUZHOU, China and SPRING HOUSE, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) and Third Arc Bio, Inc. (“Third Arc Bio”), today announced a licensing agreement under which Third Arc Bio will utilize Adagene’s SAFEbody technology platform to generate masked CD3 T cell engagers against unique tumor associated antigens. Under the terms of the agreement, Third Arc Bio will receive rights to research, develop and...

November 13, 2025 1 EN
 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene Announces First Patient Dosed in Randomized Dose Optimization ...

Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on  Patients randomized to either 10 or 20 mg/kg of muzastotug, in combination with KEYTRUDA with up to 30 patients per arm Company anticipates trial completion in early 2027, and potential updates in 2026 Additional updates from the ongoing Phase 1b/2 trial with muzastotug...

October 31, 2025 1 EN
 PRESS RELEASE
Free
ADAG Adagene ADS (N ...

Adagene Expands SAFEbody® Collaboration and License Agreement with Exe...

Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate SAN DIEGO and SUZHOU, China, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced an amendment to the 2021 . Under the terms of the amended agreement, Exelixis will utilize Adagene’s SAFEbody technology platform to generate a masked monoclonal antibody from the company’s pipeline for the development of an antibody-drug conjugate (ADC) against an Exelixis-nominated solid tumor target. Adagene is eligible to receive developm...

September 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch